Novartis’ canakinumab failed to improve survival in Phase III trial | ReutersZURICH (Reuters) –

Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing. The Phase III CANOPY-2 study was evaluating canakinumab in combination with the chemotherapy agent docetaxel in 237 adults with non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy, the Swiss drugmaker said in a statement. The canakinumab development program continues with two Phase III non-small cell lung cancer clinical trials ongoing in first-line and adjuvant settings, Novartis said. Findings will be presented at an upcoming medical meeting. Canakinumab is a human monoclonal antibody that could enhance anti-tumour immune response and reduce tumour cell proliferation, survival and invasiveness, Novartis said. #manchesterunited#manchestercity#HealthForAll#HealthBroadcastingService#QAnon#march72021#nba#brooklynnets #sacramentokings#losangeleslakers#HealthBroadcastingServiceInPublicHealthPartnership#leSamyn2021#gonzagabasketball#liverpoolfc#sanjosesharks#deutscherwetterdienst#jonathantucker#celticfc#meganmarkle#ellemiekevermolen#sacramentokings#lasvegasraiders#sanantoniospurs#kellenwinslow#pakistansuperleague#birdsofafeatherpaulinequirke#vegasgoldenknights#disneyland#glasgowwarriors#charlottehornets#sixnationschampionship#jackiebradleyjr#momentswithannie #losangeleslakers #amazonfresh#gonzagabulldogs #bobmarley#losangelesclippers#harrypotter#googleboxhttps://www.reuters.com/…/us-novartis-canakinumab…